Form 4: Candel Therapeutics CEO Sells Shares to Cover Tax Obligations

Paul Peter Tak, CEO of Candel Therapeutics, sold 21,704 shares of common stock on January 15, 2025, at a price of $7.225 per share to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On January 15, 2025, Paul Peter Tak, the CEO of Candel Therapeutics, sold 21,704 shares of the company's common stock.
• The shares were sold at a price of $7.225 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units.
• Following the transaction, Tak directly owns 251,912 shares of Candel Therapeutics.
• The sale was conducted under the issuer's mandatory sell-to-cover policy.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative view of the company's prospects.

Industry Context

Sales to cover tax obligations upon vesting of restricted stock units are a common practice among executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates